The Pharmaceutical Market: Portugal

Date: January 31, 2013
Pages: 91
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P32CAC2F770EN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Portugal
OVERVIEW OF THE PHARMACEUTICAL MARKET IN PORTUGAL

Portugal 's pharmaceutical and healthcare sector has been transformed since the intervention of the EU, IMF and ECB as part of the country's EUR78bn economic rescue package approved in May 2011 . The latest review states that Portugal has already made considerable savings in the healthcare sectors, with changes such as the introduction of e-prescriptions and prescribing by active ingredients, changes to reference pricing, reductions in pharmacy margins and price cuts just some of the measures in place. The impact on the market has been widespread. Spending has been slashed and both domestic and multinational pharmaceutical firms have seen their profits shr i nk. Data recently published by Infarmed show that Portugal has dropped from hosting 138 clinical trials in 2008 to just 87 in 2011, suggesting the country is losing its appeal as a location for research and development (R&D) . Drug shortages in pharmacies are also commonplace, with a study published by Apifarma in October 2012 suggesting that parallel exports are partly to blame.

Headline Expenditure Projections

Pharmaceuticals: EUR4.47bn (US$6.21bn) in 2011 to EUR4.24bn (US$5.39bn) in 2012; -5.1% in local currency and -13.3% in US dollar terms. Forecast raised slightly from Q 4 12 because of new historical data.

Healthcare: EUR19.59bn (US$27.22bn) in 2011 to EUR20.16bn (US$25.60bn) in 2012; +2.9% in local currency and -6.0% in US dollar terms. Forecast raised from Q 4 12 because of new historical data.

Medical devices: EUR740mn (US$1.03bn) in 2011 to EUR763mn (US$0.97bn) in 2012; +3.1% in local currency and -5.8% in US dollar terms. Forecast unchanged from Q 4 12.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

SWOT ANALYSIS

    Portugal Pharmaceuticals And Healthcare Industry SWOT
    Portugal Political SWOT
    Portugal Economic SWOT
    Portugal Business Environment SWOT

PHARMACEUTICAL RISK/REWARD RATINGS

    Table: Western Europe Pharmaceutical Risk/Reward Ratings, Q113
    Rewards
    Risks

PORTUGAL – MARKET SUMMARY

REGULATORY REGIME

    Parallel Imports
    Recent EU Regulatory Developments
    Pricing Regime
    Patented Products
    Generic Drugs
    OTC Medicines
    Reimbursement Regime
    Pharmacoeconomics

INDUSTRY TRENDS AND DEVELOPMENTS

    Epidemiology
    Healthcare System
    Hospital Infrastructure And Services
    Outpatient Infrastructure And Services
    Pharmaceutical Industry
    Company Developments
    Wholesale Sector
    Pharmacy Sector
    Clinical Research
    Medical Devices

INDUSTRY FORECAST SCENARIO

  Overall Market Forecast
    Table: Pharmaceutical Sales Indicators 2008-2016
  Key Growth Factors – Industry
    Table: Healthcare Expenditure Indicators 2008-2016
    Table: Healthcare Governmental Indicators 2008-2016
    Table: Healthcare Private Indicators 2008-2016
    Table: Portugal - Economic Activity
    Prescription Drug Market Forecast
    Table: Prescription Drug Sales Indicators 2008-2016
    Patented Drug Market Forecast
    Table: Patented Drug Market Indicators 2008-2016
    Generic Drug Market Forecast
    Table: Generic Drug Sales Indicators 2008-2016
    Table: Top Generic Drugs By Value In 2011
    Table: Average Price Of Top Generic Drugs By Value 2010-2011
    OTC Medicine Market Forecast
    Table: OTC Medicine Sales Indicators 2008-2016
    Table: OTC Sales Outside Of Pharmacies By Therapeutic Group (Jan-June 2012)
    Table: OTC Sales Outside Of Pharmacies By District (Jan-June 2012)
    Table: OTC Sales Outside Of Pharmacies By Sales Outlet (Jan-June 2012)
    Table: Portugal OTC Sales Outside Of Pharmacies By Active Ingredient (Jan-June 2012)
    Pharmaceutical Trade Forecast
    Table: Exports and Imports Indicators 2008-2016
    Other Healthcare Data Forecasts
    Key Risks To BMI’s Forecasts

COMPETITIVE LANDSCAPE

    Table: Number Of Pharmaceutical Companies, Wholesalers, Pharmacies, Pharmacy Extensions And Drug Stores In Portugal

COMPANY PROFILES

    Hovione
    Bial
    Medinfar
    Bluepharma

DEMOGRAPHIC OUTLOOK

    Table: Population By Age Group, 1990-2020 (‘000)
    Table: Population By Age Group, 1990-2020 (% of total)
    Table: Key Population Ratios, 1990-2020
    Table: Rural And Urban Population, 1990-2020

GLOSSARY

BMI METHODOLOGY

    How We Generate Our Pharmaceutical Industry Forecasts
    Pharmaceuticals Business Environment Ratings
    Risk/Reward Ratings Methodology
    Ratings Overview
    Table: Pharmaceutical Business Environment Indicators
    Weighting
    Table: Weighting Of Components
    Sources
Skip to top


The Pharmaceutical Market: Czech Republic US$ 1,295.00 Jan, 2013 · 90 pages
The Pharmaceutical Market: Egypt US$ 1,295.00 Jan, 2013 · 111 pages
The Pharmaceutical Market: Finland US$ 1,295.00 Mar, 2013
The Pharmaceutical Market: France US$ 1,295.00 Jan, 2013 · 107 pages

Ask Your Question

The Pharmaceutical Market: Portugal
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: